Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAT: Optimal Timing of HIV Therapy After Cryptococcal Meningitis
NCT01075152Phase 4Completed
- Sponsor
- University of Minnesota
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) and cryptococcal meningitis (2 arms), sponsored by University of Minnesota. Primary endpoint: Mortality at 26 weeks. Started Nov 2010; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)cryptococcal meningitis
Beyond the preview
Go deeper on NCT01075152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01075152.